Literature DB >> 23185687

Interventions for the metabolic syndrome in schizophrenia: a review.

Evangelos Papanastasiou1.   

Abstract

The metabolic syndrome (MetS) is an increasingly prevalent condition in people with schizophrenia. It remains highly prevalent in the general population in developed countries, but recently health promotion campaigns and greater awareness of the high associated mortality rates have resulted in improvements in the rates of cardiovascular risk factors. This is not the case for people with schizophrenia who continue to have more than twice the rates of MetS and significantly higher mortality rates than the general population. Various behavioural and pharmacological interventions have been used to improve conditions that are linked to MetS, mainly smoking and obesity. This review aims to provide an update of the latest knowledge about the behavioural, pharmacological and other interventions that might help to combat this life-threatening problem in people with schizophrenia.

Entities:  

Keywords:  Antipsychotic-induced weight gain; cardiovascular risk factors; diabetes; metabolic syndrome; obesity; physical exercise; physical health intervention; schizophrenia; smoking cessation; weight reduction/management

Year:  2012        PMID: 23185687      PMCID: PMC3498847          DOI: 10.1177/2042018812458697

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  119 in total

1.  Effect of amantadine on weight gain during olanzapine treatment.

Authors:  M Floris; J Lejeune; W Deberdt
Journal:  Eur Neuropsychopharmacol       Date:  2001-04       Impact factor: 4.600

2.  Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.

Authors:  Evgueni Tchoukhine; Pirjo Takala; Helinä Hakko; Mirjam Raidma; Hanna Putkonen; Pirkko Räsänen; Viacheslav Terevnikov; Jan-Henry Stenberg; Markku Eronen; Grigori Joffe
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

3.  Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.

Authors:  Karen A Graham; Hongbin Gu; Jeffrey A Lieberman; Joyce B Harp; Diana O Perkins
Journal:  Am J Psychiatry       Date:  2005-09       Impact factor: 18.112

4.  At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

Authors:  Thomas Hansen; Andrés Ingason; Srdjan Djurovic; Ingrid Melle; Mogens Fenger; Omar Gustafsson; Klaus D Jakobsen; Henrik B Rasmussen; Sarah Tosato; Marcella Rietschel; Josef Frank; Mike Owen; Chiara Bonetto; Jaana Suvisaari; Johan Hilge Thygesen; Hannes Pétursson; Jouko Lönnqvist; Engilbert Sigurdsson; Ina Giegling; Nick Craddock; Michael C O'Donovan; Mirella Ruggeri; Sven Cichon; Roel A Ophoff; Olli Pietiläinen; Leena Peltonen; Markus M Nöthen; Dan Rujescu; David St Clair; David A Collier; Ole A Andreassen; Thomas Werge
Journal:  Biol Psychiatry       Date:  2011-03-16       Impact factor: 13.382

5.  Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.

Authors:  Elaine Weiner; Alison Buchholz; Agnes Coffay; Fang Liu; Robert P McMahon; Robert W Buchanan; Deanna L Kelly
Journal:  Schizophr Res       Date:  2011-03-04       Impact factor: 4.939

6.  A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.

Authors:  Soroor Arman; Mohammad R Sadramely; Mortaza Nadi; Navid Koleini
Journal:  Saudi Med J       Date:  2008-08       Impact factor: 1.484

Review 7.  Schizophrenia and weight management: a systematic review of interventions to control weight.

Authors:  G Faulkner; A A Soundy; K Lloyd
Journal:  Acta Psychiatr Scand       Date:  2003-11       Impact factor: 6.392

Review 8.  Schizophrenia and sudden cardiac death: a review.

Authors:  Hannu Koponen; Antti Alaräisänen; Kaisa Saari; Olavi Pelkonen; Heikki Huikuri; M J Pekka Raatikainen; Markku Savolainen; Matti Isohanni
Journal:  Nord J Psychiatry       Date:  2008       Impact factor: 2.202

Review 9.  Behavioural interventions to reduce the risk of physical illness in persons living with mental illness.

Authors:  Vivien Kemp; Ann Bates; Mohan Isaac
Journal:  Curr Opin Psychiatry       Date:  2009-03       Impact factor: 4.741

10.  Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

Authors:  Michael Poyurovsky; Camil Fuchs; Artashez Pashinian; Aya Levi; Sarit Faragian; Rachel Maayan; Irit Gil-Ad
Journal:  Psychopharmacology (Berl)       Date:  2007-02-20       Impact factor: 4.415

View more
  10 in total

Review 1.  Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-07-15       Impact factor: 3.911

Review 2.  Primary care-based educational interventions to decrease risk factors for metabolic syndrome for adults with major psychotic and/or affective disorders: a systematic review.

Authors:  Cynthia Nover; Sarah S Jackson
Journal:  Syst Rev       Date:  2013-12-27

3.  Physical performance and disability in schizophrenia.

Authors:  M Strassnig; J Signorile; C Gonzalez; P D Harvey
Journal:  Schizophr Res Cogn       Date:  2014-06

4.  Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana.

Authors:  Angela Owusu-Ansah; Anto Berko Panyin; Christian Obirikorang; Christian Agyare; Emmanuel Acheampong; Simon Kwofie; Enoch Odame Anto; Emmanuella Nsenbah Batu
Journal:  Schizophr Res Treatment       Date:  2018-06-28

5.  Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia-A Systematic Review.

Authors:  Ewa Tumiel; Adam Wichniak; Marek Jarema; Michał Lew-Starowicz
Journal:  Front Psychiatry       Date:  2019-08-16       Impact factor: 4.157

6.  Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis.

Authors:  Pruntha Kanagasundaram; Jiwon Lee; Femin Prasad; Kenya A Costa-Dookhan; Laurie Hamel; Madeleine Gordon; Gary Remington; Margaret K Hahn; Sri Mahavir Agarwal
Journal:  Front Psychiatry       Date:  2021-03-17       Impact factor: 4.157

7.  Effectiveness of a complex psychosocial intervention to reduce metabolic syndrome in psychiatric outpatients with severe/persistent mental illness.

Authors:  Barna Konkolÿ Thege; Talia Emmanuel; Stephanie Hill; Laurie Wells
Journal:  Curr Psychol       Date:  2021-09-12

8.  Metabolic syndrome, serious mental illnesses & lifestyle.

Authors:  R Padmavati
Journal:  Indian J Med Res       Date:  2016-04       Impact factor: 2.375

9.  Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service.

Authors:  Andrew Shaker; Rowena Jones
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-19

Review 10.  Tackling obesity in mental health secure units: a mixed method synthesis of available evidence.

Authors:  Maxine Johnson; Matthew Day; Rajesh Moholkar; Paul Gilluley; Elizabeth Goyder
Journal:  BJPsych Open       Date:  2018-07-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.